Publications by authors named "M BRIERE"

Objective: Pituitary stalk interruption syndrome (PSIS) is a rare cause of congenital hypopituitarism. Limited data exist on the gonadotropic status and fertility of adult women with PSIS. Our study aims to describe pubertal development and the evolution of gonadotropic function and fertility in adult women with PSIS.

View Article and Find Full Text PDF

Background: Recent research suggests a need for worksite programs that promote structured physical activity (PA) among hospital staff. The objectives of this study were to assess the hospital employees' acceptance of PA opportunities that could be implemented at the worksite, and the association between worksite PA and commuting and other sociocognitive factors.

Method: Acceptance of seven PA opportunities from the WHO guidelines was correlated with commuting and socio-cognitive factors through an online survey conducted among the workforce of the University Hospital of Angers, France ( = 6874) between April 25 and May 22, 2022.

View Article and Find Full Text PDF

Cemiplimab, a human monoclonal antibody directed against PD-1, has provided more options in the treatment of locally advanced or metastatic cutaneous squamous-cell carcinoma at an unresectable state. Immune checkpoint inhibitors can induce several unfavorable reactions generally referred to as immune-related adverse effects. Cytokine-release syndrome is an immune-related adverse event that is infrequent and not well known.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to compare the immune responses of two mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) to see if mixing them for the second dose produces a similar immune effect as receiving the same vaccine for both doses.
  • - Nearly 400 adults participated, receiving either the same vaccine for both doses or a mix; the results showed that mixing the vaccines resulted in different antibody levels.
  • - Overall, the research suggests that using either vaccine interchangeably is safe and effective, but those who received mRNA-1273 as a second dose reported more side effects compared to those who got BNT162b2.
View Article and Find Full Text PDF